Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.

Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.

Forty percent of patients with diffuse large B-cell lymphoma (DLBCL) show resistant disease to standard chemotherapy (CHOP) in combination with the anti-CD20 monoclonal antibody rituximab (R). Although many new anti-cancer drugs were developed in the last years, it is unclear which of these drugs ca...

Full description

Bibliographic Details
Main Authors: Mathilde R W de Jong, Lydia Visser, Gerwin Huls, Arjan Diepstra, Marcel van Vugt, Emanuele Ammatuna, Rozemarijn S van Rijn, Edo Vellenga, Anke van den Berg, Rudolf S N Fehrmann, Tom van Meerten
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5831110?pdf=render

Internet

http://europepmc.org/articles/PMC5831110?pdf=render

Similar Items